Pancreatic Cancer Treatment: Surgery, FOLFIRINOX, and Targeted Care

Last updated and reviewed on June 24, 2026.

Treatment for pancreatic cancer depends on the type of tumor, its stage, where it is located, whether it can be surgically removed, and the patient's overall health and personal goals. Because pancreatic cancer treatment involves complex surgical decisions, chemotherapy regimens with significant side effects, and in many cases radiation, the best care happens at centers that treat high volumes of pancreatic cancer patients with a dedicated multidisciplinary team. That team typically includes a pancreatic surgeon, a medical oncologist, a radiation oncologist, a gastroenterologist, a radiologist, a pathologist, and a palliative care specialist, all working together.

This guide walks through the main treatment options for pancreatic ductal adenocarcinoma (PDAC), which is the most common type, and briefly covers treatment approaches for pancreatic neuroendocrine tumors (PNETs).

Surgery

Surgery is the only treatment that offers a realistic chance of curing pancreatic ductal adenocarcinoma. Unfortunately, only about 15 to 20 percent of PDAC patients have tumors that are surgically removable at the time of diagnosis. For those who do, surgery followed by chemotherapy gives the best chance of long-term survival.

• The Whipple Procedure (Pancreaticoduodenectomy): This is the most common surgery for pancreatic cancer in the head of the pancreas. It is a major operation in which the surgeon removes the head of the pancreas, the first part of the small intestine (the duodenum), the gallbladder, part of the bile duct, and sometimes part of the stomach. The remaining pancreas, bile duct, and stomach (or duodenum) are then reconnected to the small intestine to allow digestion to continue. The Whipple procedure takes several hours and requires a recovery time of several weeks to a few months. It is one of the most complex abdominal operations performed, which is why outcomes are significantly better at high-volume centers.
• Distal Pancreatectomy: For tumors in the body or tail of the pancreas, the left side of the pancreas is removed along with the spleen in a procedure called a distal pancreatectomy. Because tumors in the body and tail of the pancreas tend not to block the bile duct, they often do not cause jaundice and may grow larger before being detected, which is part of why cancers in this location are often found at a later stage.
• Total Pancreatectomy: In some cases, the entire pancreas must be removed. This is less common but is sometimes done for tumors that span the entire gland or when partial removal cannot achieve adequate margins. Removing the entire pancreas means the patient will have permanent diabetes and will need to take digestive enzyme supplements for the rest of their life.
• Minimally Invasive Surgery: Laparoscopic and robotic approaches to pancreatic surgery are increasingly available at specialized centers for selected patients. These approaches can reduce surgical blood loss, shorten hospital stays, and speed recovery, though they require particular surgical expertise and are not appropriate for all tumors.

Chemotherapy

Chemotherapy is a central part of pancreatic cancer treatment at every stage, whether given before surgery (neoadjuvant), after surgery (adjuvant), or as the main treatment for patients who cannot have surgery.

• FOLFIRINOX: The FOLFIRINOX regimen, which combines four drugs (leucovorin, fluorouracil, irinotecan, and oxaliplatin), is one of the two most effective chemotherapy options for pancreatic cancer. In patients who are physically fit enough to tolerate it, FOLFIRINOX significantly improves survival compared to gemcitabine alone and is often the preferred option for first-line treatment in younger, healthier patients with metastatic disease and for neoadjuvant treatment in patients with borderline resectable or locally advanced disease.
• Gemcitabine plus Nab-paclitaxel: This combination of gemcitabine and albumin-bound paclitaxel (nab-paclitaxel, sold as Abraxane) is another major first-line option for metastatic PDAC. It improved survival compared to gemcitabine alone in a large clinical trial and is often preferred for patients who may not tolerate the full FOLFIRINOX regimen because of age or other health conditions.
• Gemcitabine alone: While less effective than the combinations above, gemcitabine alone remains an option for patients who cannot tolerate more intensive regimens. It was the standard of care for metastatic pancreatic cancer for many years before the combination regimens were developed.
• Adjuvant chemotherapy after surgery: For patients who have surgery, adjuvant (post-surgery) chemotherapy significantly reduces the risk of recurrence and extends survival. The current standard is either modified FOLFIRINOX for 6 months or gemcitabine plus capecitabine for 6 months. Adjuvant treatment is typically recommended to begin within 6 to 12 weeks of surgery.
• PARP inhibitors (olaparib): For patients with metastatic PDAC who have germline BRCA1 or BRCA2 mutations and whose cancer has not progressed on first-line platinum-based chemotherapy, maintenance therapy with olaparib (Lynparza) is FDA-approved and has been shown to extend the time before the cancer progresses.

Radiation Therapy

The role of radiation in pancreatic cancer is more complex and somewhat more debated than in some other cancers. It is used in specific situations.

• For locally advanced unresectable disease: Radiation combined with chemotherapy (chemoradiation) is used to try to control tumor growth. This can sometimes convert a locally advanced tumor to a resectable one, in which case surgery becomes possible.
• For borderline resectable tumors: Some centers use neoadjuvant chemoradiation alongside or instead of chemotherapy to try to shrink the tumor and improve surgical margins.
• After surgery, Radiation: Sometimes considered if the surgical margins are close or positive (meaning cancer cells were found at the edge of the removed tissue), though the benefit of adjuvant radiation is not as clearly established as the benefit of adjuvant chemotherapy.
• Stereotactic body radiation therapy (SBRT): A newer, more precise form of radiation that delivers high doses of radiation to the tumor in a small number of treatments (usually 5 or fewer), with much greater accuracy than traditional radiation. SBRT is increasingly used for locally advanced pancreatic cancer and is being studied in clinical trials for other stages.

Targeted Therapy

As molecular profiling of pancreatic tumors has become more common, targeted treatment options have emerged for specific patient subgroups.

• Olaparib (Lynparza): A PARP inhibitor approved for maintenance treatment in patients with germline BRCA1 or BRCA2 mutations after platinum-based chemotherapy, as noted above.
• Pembrolizumab (Keytruda): An immunotherapy checkpoint inhibitor that is FDA-approved for any solid tumor with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). A small percentage of pancreatic cancers (roughly 1 to 2 percent) have this feature, and those that do may respond dramatically to pembrolizumab.
• TRK inhibitors: Larotrectinib (Vitrakvi) and entrectinib (Rozlytrek) are approved for tumors with NTRK gene fusions, which are extremely rare in pancreatic cancer but can occur. When present, these fusions predict very good responses to TRK inhibitor therapy.
• Sotorasib and adagrasib: Targeting the KRAS G12C mutation. While the more common KRAS G12D and G12V mutations seen in pancreatic cancer are not yet directly targetable by approved drugs, the rapid pace of research in KRAS-directed therapy means new options for pancreatic cancer patients may emerge in the coming years.

Treatment for Pancreatic Neuroendocrine Tumors (PNETs)

PNETs are treated differently from PDAC.

• Surgery: The main treatment when possible and can be curative for localized PNETs.
• For unresectable or metastatic PNETs: Treatment options include somatostatin analogues (like octreotide and lanreotide, which can control symptoms and slow tumor growth)
• Targeted therapies: (everolimus and sunitinib, which are both FDA-approved for progressive PNETs), peptide receptor radionuclide therapy (PRRT, which uses a radioactive compound to target and destroy neuroendocrine tumor cells)
• Chemotherapy: For high-grade neuroendocrine carcinomas.

Supportive and Palliative Care for Pancreatic Cancer

Supportive care, also called palliative care, is not the same as hospice care and does not mean giving up on treatment. It means addressing the symptoms, side effects, nutritional needs, and emotional burdens of pancreatic cancer alongside active treatment, from the time of diagnosis forward. Research in other cancers has shown that early palliative care can improve quality of life and even extend survival.

For pancreatic cancer specifically, key elements of supportive care include:

• Pain management: One of the most important aspects of pancreatic cancer care. Tumor growth near the celiac nerve plexus (a cluster of nerves in the back of the abdomen) can cause severe, difficult-to-control pain. In addition to medications, a procedure called celiac plexus neurolysis (a nerve block that numbs the celiac plexus) can dramatically reduce pain in some patients and reduce the need for high doses of opioid medications.
• Pancreatic enzyme replacement therapy (PERT): Critical for patients with pancreatic cancer because the tumor disrupts the production of digestive enzymes. Without adequate enzymes, patients cannot properly absorb fat and other nutrients, leading to malnutrition, weight loss, and greasy diarrhea. Enzyme replacement capsules (like Creon) taken with every meal can dramatically improve nutritional status and quality of life.
• Nutritional support: Dietitians experienced in cancer care are invaluable. Maintaining weight and muscle mass during treatment improves tolerance of chemotherapy and overall outcomes.
• Biliary stenting: Relieves bile duct obstruction (and the jaundice, itching, and digestive problems it causes) is performed through ERCP or surgically in patients with tumors blocking the bile duct.
• Emotional and psychological support: Social workers, counselors, or psychologists who specialize in cancer is important for both patients and their families. Anxiety, depression, and existential distress are common, and addressing them as genuine medical concerns improves quality of life.
• Palliative care consultation: Can be offered early to all patients with advanced pancreatic cancer, and ideally to all patients at diagnosis. A palliative care team focuses on comfort, symptom control, communication about goals, and support for both the patient and their family.

Follow-Up Care After Treatment Ends

For patients who have had surgery and completed adjuvant chemotherapy, regular follow-up care is essential. Pancreatic cancer has a high rate of recurrence even after successful surgery, and follow-up monitoring helps detect recurrence as early as possible and manage any long-term effects of treatment.

Follow-up typically involves a physical exam, blood tests including CA 19-9, and a CT scan every 3 to 6 months for the first two years, then every 6 to 12 months thereafter. The exact schedule depends on your individual situation. Managing the ongoing effects of surgery, like new-onset diabetes, malabsorption requiring enzyme supplementation, and changes in digestive patterns, is also an ongoing part of post-treatment care.

For patients with locally advanced or metastatic disease who are receiving ongoing chemotherapy, regular monitoring of response (through imaging and CA 19-9) helps guide decisions about whether to continue, modify, or change treatment. Connecting with a survivorship care program, staying in close contact with your care team, and reporting new symptoms promptly gives you the best chance of staying ahead of any problems.

Sources

1. National Cancer Institute. Pancreatic Cancer Treatment (PDQ) Patient Version. https://www.cancer.gov/types/pancreatic/patient/pancreatic-treatment-pdq
2. National Comprehensive Cancer Network (NCCN). NCCN Guidelines: Pancreatic Adenocarcinoma. 2024. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455
3. Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine. 2011;364(19):1817-1825. https://pubmed.ncbi.nlm.nih.gov/21561347/
4. Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine. 2013;369(18):1691-1703. https://www.nejm.org/doi/full/10.1056/NEJMoa1304369
5. Golan T, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. New England Journal of Medicine. 2019;381(4):317-327. https://www.nejm.org/doi/full/10.1056/NEJMoa1903387
6. Conroy T, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. New England Journal of Medicine. 2018;379(25):2395-2406. https://www.nejm.org/doi/full/10.1056/NEJMoa1809775
7. Temel JS, et al. Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2010;363:733-742. https://www.nejm.org/doi/full/10.1056/NEJMoa1000678
8. Pancreatic Cancer Action Network. Treatment. https://www.pancan.org/facing-pancreatic-cancer/learn/treatment/